| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Upregulated in MDS patients with U2AF1 mutations; knockdown had less marked effects, with only one gene significantly upregulated. |
| Molecular mechanism: |
Predicted miRNA interaction analysis was performed, but no specific validated mechanism was established for circZNF609 in U2AF1-mutated MDS. |
| Biological pathway or process: |
ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
S
|
| Validation methods: |
RNA-seq; Clinical Sample Validation; Bioinformatics Analysis; Transfection; RT-qPCR |
| Clinical significance: |
Potential biomarker and therapeutic target investigation in U2AF1-mutated MDS. |
| Description: |
circZNF609 was upregulated in MDS patients with U2AF1 mutations and selected for knockdown because it was highly expressed in U2AF1-mutated K562 clones and previously described in cancer. Its knockdown had limited transcriptional effects compared with circCSNK1G3 and circMAN1A2. |
| Confidence score: |
0.4997 |